Print
28 March 2018
GMP News
During his working visit to Switzerland, the President of the Republic of Tatarstan Rustam Minnikhanov visited the headquarters of Ferring, a pharmaceutical company.
In the Republic of Tatarstan, Ferring is represented by Nanopharma Development, a company. The production facility is located in Khimgrad Technopolis. The first industrial lot of a drug for the needs of transplantology was manufactured in Q3 2017. The drug for treatment of myeloid leukemia was produced in Q4 2017. Another 10 medicines are being developed for the treatment of oncological diseases, HIV, organ and tissue transplantation, and some orphan diseases. The plans for 2018 provide for completing the construction of a new site for sterile drugs for women’s health and treatment of infertility, and other vital medicines.
The meeting also discussed the project “North” to establish the manufacturing of active pharmaceutical substances by enzymatic and organic synthesis. Production center will be fitted with laboratory and pilot manufacturing equipment to make three active pharmaceutical substances at the first stage, including those for organ and tissue transplantation. These substances are not yet manufactured in Russia. The facility is scheduled for launch in 2021-2022.
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.